Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.

ABSTRACT: Despite the uncertainty of the pathogenesis of systemic lupus erythematosus, novel small molecules targeting specific intracellular mechanisms of immune cells are being developed to reverse the pathophysiological processes. These targeted molecules have the advantages of convenient administration, lower production costs, and the lack of immunogenicity. The Janus kinases, Bruton's tyrosine kinases, and spleen tyrosine kinases are important enzymes for activating downstream signals from various receptors on immune cells that include cytokines, growth factor, hormones, Fc, CD40, and B-cell receptors. Suppression of these kinases impairs cellular activation, differentiation, and survival, leading to diminished cytokine actions and autoantibody secretion. Intracellular protein degradation by im

SUBMITTER: Mok CC 

PROVIDER: S-EPMC10042116 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature